OncoBeta Announces Approval and ARTG Listing of Rhenium-SCT (Rhenium-188 paste) in Australia for the treatment of skin cancer lesions and skin tumors
By: OncoBeta GmbH
The global incidence of non-melanoma skin cancers has drastically increased over the past few decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia having one of the highest incidence rates in the world. According to the Australian Institute of Health and Welfare (AIHW) Non-melanoma skin cancer (NMSC) is the most common cancer diagnosed in Australia, with over 400,000 new cases per year.
"The approval of the Rhenium-SCT in Australia is a great step forward for patients wanting a new non-invasive and painless treatment option for Non-Melanoma Skin cancer," said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. "We are committed to bringing back quality of life to skin cancer sufferers."
Nicholas H. Vetter, Chief Operating Officer of OncoBeta said, "After receiving the TGA approval we will now set up local production to make the Rhenium-SCT even more accessible to clinics, physicians and their patients throughout Australia."
About the Rhenium-SCT®
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-
Find out more about the Rhenium-SCT®
Follow us on social media:
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
OncoBeta GmbH - Marketing/Public Relations
Schleißheimer Str. 91
85748 Garching n. Munich GERMANY
+49 (89) 32667330